Astellas Pharma

Astellas Pharma EBITDA per Share

The EBITDA per Share of Astellas Pharma (4503.T) as of Nov 21, 2026 is 232.97 JPY. In the previous year, EBITDA per Share was 218.34 JPY — a change of 6.70% (higher).

EBITDA per Share

232.97JPY

YoY

6.70%

Last updated:

EBITDA per Share of Astellas Pharma is 2026 232.97 JPY. EBITDA per Share of Astellas Pharma was 2025 218.34 JPY. It decreases by 6.70% higher compared to the previous year.

The Astellas Pharma EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
168.09 JPY
Jan 1, 2020
161.73 JPY
Jan 1, 2021
148.16 JPY
Jan 1, 2022
136.17 JPY
Jan 1, 2023
179.90 JPY
Jan 1, 2024
154.71 JPY
Jan 1, 2025
218.34 JPY
Jan 1, 2026
232.97 JPY
The Astellas Pharma EBITDA per Share history
YEAREBITDA per ShareYoY
232.97JPY+6.70%
218.34JPY+41.13%
154.71JPY-14.01%
179.90JPY+32.12%
136.17JPY-8.09%
148.16JPY-8.39%
161.73JPY-3.78%
168.09JPY+5.29%
159.65JPY+3.20%
154.69JPY+4.95%
147.40JPY+24.42%
118.47JPY+18.65%
99.85JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Astellas Pharma Stock analysis

What does Astellas Pharma do? Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Astellas Pharma stock

EBITDA per Share of Astellas Pharma is 232.97 JPY in 2026.

EBITDA per Share of Astellas Pharma changed from 218.34 JPY to 232.97 JPY, representing a 6.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Astellas Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Astellas Pharma

All Key Metrics — Astellas Pharma